Home - Forschungszentrum Borstel, Leibniz Lungenzentrum

die-lunge-im-fokus-fzb.jpg

Focus on the lungs

We are the lung research center of the Leibniz Association.
Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).

Our Mission

die-lunge-im-fokus-fzb.jpg

Chronic lung diseases

The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.

Priority Research Area

die-lunge-im-fokus-fzb.jpg

Infections

The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis.
The aim is to improve the control and treatment of this disease.

To the program area

die-lunge-im-fokus-fzb.jpg

Science & Technology

This area combines overarching research units that are essential for research at the FZB and represent an important link between the subject areas.

Further Information

News

07.10.2025

Another ECDC training successfully finished

International specialists deepened their knowledge of genome data analysis of tuberculosis pathogens in a one-week training course at the Research Center Borstel, Leibniz Lung Center.
02.10.2025

Tuberculosis and Migration: Protecting the Most Vulnerable

Tuberculosis (TB) remains one of the world’s most dangerous infectious diseases – and it affects people on the move particularly hard. In Germany, nearly three out of four TB cases are found in people who were not born in the country. How migration, poverty, and war are shaping the spread of TB in Europe was the focus of a symposium organized by the Research Center Borstel, Leibniz Lung Center (FZB), at the 14th Congress for Tropical Medic
01.10.2025

Antibiotic resistance can also make bacteria more vulnerable

Antibiotic resistance is one of the greatest challenges in modern medicine. A new study now shows that Haemophilus influenzae can rapidly adapt to commonly used beta-lactam antibiotics. However, the genetic changes and their consequences are surprisingly diverse and difficult to predict. Some mutations even make the bacteria more susceptible to other drugs.